probenecid has been researched along with Acute Myelogenous Leukemia in 2 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Copsel, S | 1 |
| Garcia, C | 1 |
| Diez, F | 1 |
| Vermeulem, M | 1 |
| Baldi, A | 1 |
| Bianciotti, LG | 1 |
| Russel, FG | 1 |
| Shayo, C | 1 |
| Davio, C | 1 |
| Kim, HS | 1 |
| Min, YD | 1 |
| Choi, CH | 1 |
2 other studies available for probenecid and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.
Topics: Cell Differentiation; Cell Division; Cyclic AMP; Drug Design; HL-60 Cells; Humans; Leukemia, Myeloid | 2011 |
Double-edged sword of chemosensitizer: increase of multidrug resistance protein (MRP) in leukemic cells by an MRP inhibitor probenecid.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette | 2001 |